KAT6B Antibodies

Structure of KAT6B

The protein encoded by the KAT6B gene is a histone acetyltransferase with a molecular weight of approximately 800 kDa. The core domain of this protein is highly conserved among different species, but the sequence lengths and compositions of the non-core regions (such as acidic domains) vary, which may lead to changes in its binding specificity to different interacting proteins.

The core of this protein lies in its MYST domain, which is crucial for its histone acetyltransferase activity. This domain forms a unique three-dimensional structure consisting of a "zinc finger" and an "acetyl-CoA binding pocket", enabling it to precisely recognize and catalyze the acetylation of specific lysine residues (such as K9, K14, K23) of histone H3. The acidic N-terminal domain exists in a relatively loose and disordered conformation, mainly responsible for recruiting other transcriptional co-activators and forming a large transcriptional regulatory complex, thereby regulating the expression of downstream target genes.

Fig. 1 Cartoon Depiction of KAT6B Germline Mutants in Intellectual Disability.¹

Key structural properties of KAT6B:

• Core MYST domain with conserved acetyl-coa binding pocket
• N and C terminal containing long disordered area, responsible for protein interactions
• The key cysteine residues are involved in zinc ion coordination and stabilize structural folding

Functions of KAT6B

The core function of the protein encoded by the KAT6B gene is to act as a histone acetyltransferase, catalyzing the acetylation modification of specific lysine residues (such as K9, K14, K23) of histone H3. However, it is also a key component of large transcriptional co-activator complexes (such as the MOZ/MORF complex), participating in the regulation of a wide range of physiological and pathological processes.

The functional characteristics of this protein lie in the fact that it is not an isolated "writing" enzyme, but rather a "core organizer". It alters the chromatin state through its enzymatic activity, and simultaneously integrates upstream signals through its protein interaction domain and assembles downstream effectors, thereby precisely controlling the expression program of specific genes at specific times and locations. The disease spectrum resulting from its dysfunction directly reflects its central hub role in development and homeostasis maintenance.

Applications of KAT6B and KAT6B Antibody in Literature

1. Zu, Gaoyu, et al. "BRPF1-KAT6A/KAT6B complex: molecular structure, biological function and human disease." Cancers 14.17 (2022): 4068. https://doi.org/10.3390/cancers14174068 

The article indicates that BRPF1 is a key scaffold protein of the KAT6A/KAT6B acetyltransferase complex. This complex is involved in histone modification, and mutations in its member genes are closely related to various diseases such as intellectual disability, leukemia and medulloblastoma, and have become potential therapeutic targets.

2. Liu, Yingzi, et al. "KAT6B may be applied as a potential therapeutic target for glioma." Journal of Oncology 2022.1 (2022): 2500092. https://doi.org/10.1155/2022/2500092 

The article indicates that KAT6B is highly expressed in glioma and inhibits ferroptosis by epigenetically upregulating STAT3, thereby promoting tumor cell survival, reducing apoptosis, and decreasing lipid ROS and iron accumulation, thereby advancing the progression of glioma.

3. Bergamasco, Maria I., et al. "KAT6B overexpression rescues embryonic lethality in homozygous null KAT6A mice restoring vitality and normal lifespan." Nature Communications 16.1 (2025): 1958. https://doi.org/10.1038/s41467-025-57155-4  

The article indicates that in the KAT6A-deficient mouse model, the overexpression of KAT6B can completely compensate for its functional defect, restore hematopoietic stem cell generation and key histone modification, and reverse abnormal gene expression. This indicates that the functions of the two are substitutable.

4. Hamaguchi, Yo, et al. "KAT6B-related disorder in a patient with a novel frameshift variant (c. 3925dup)." Human genome variation 6.1 (2019): 54. https://doi.org/10.1038/s41439-019-0085-3 

The article indicates that heterozygous truncated variations in the KAT6B gene are associated with congenital rare diseases. This article reports a case of a Japanese patient carrying a novel frameshift mutation in exon 18, further confirming the association between this regional variation and the genital-patellar syndrome-like phenotype.

5. Kommoss, Felix KF, et al. "Uterine mesenchymal tumours harboring the KAT6B/A:: KANSL1 gene fusion represent a distinct type of uterine sarcoma based on DNA methylation profiles." Virchows Archiv 485.5 (2024): 793-803. https://doi.org/10.1007/s00428-024-03935-0

The article indicates that uterine stromal tumors carrying the KAT6B/A::KANSL1 fusion gene should be regarded as an independent disease type. Such tumors usually present as low-grade forms, but a few high-grade cases have unique methylation characteristics and are associated with aggressive behavior and an increased risk of patient death.

Creative Biolabs: KAT6B Antibodies for Research

Creative Biolabs specializes in the production of high-quality KAT6B antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom KAT6B Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our KAT6B antibodies, custom preparations, or technical support, contact us at email.